Note: Ozempic , Rybelsus , Mounjaro , Victoza , and metformin are not FDA-approved to treat obesity or for weight loss
To compare options accurately, always verify what is included and what the ongoing costs will be
If using an 8mg/mL tirzepatide formulation, the volumes differ
Weight loss Available in NZ = Liraglutide high dose (Saxenda, daily injection) Self-funding needed ($500-600/month) Not available in NZ = Semaglutide (Ozempic, Wegovy) or Tirzepatide (Mounjaro), as of May 2023 Side effects, particularly upper gastrointestinal, are common with GLP-1 agonist initiation
GLP-1 has revolutionized diabetes and obesity treatment, while GLP-2 offers hope for those with serious intestinal disorders